Skip to main content

ASH 2016 - Multiple Myeloma

Conference Correspondent, ASH 2016 - Multiple Myeloma
Findings from the Connect MM Registry: Changes in Treatment Patterns in Patients with Newly Diagnosed Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Carfilzomib, Pomalidomide, and Dexamethasone in Patients with Relapsed and/or Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Elotuzumab, Lenalidomide, and Dexamethasone in Patients with High-Risk Smoldering Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Response-Adapted Therapy for Newly Diagnosed Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Treatment with a Novel HDAC6 Inhibitor plus Pomalidomide and Dexamethasone in Relapsed/Refractory Multiple Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Sustained Overall Survival in Patients with Smoldering Myeloma Receiving Lenalidomide-Based Therapy
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Lenalidomide Is a Highly Effective Maintenance Therapy in Myeloma Patients of All Ages
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Health-Related Quality of Life of Patients with Newly Diagnosed Multiple Myeloma Receiving Lenalidomide Maintenance: Data from the Connect MM Disease Registry
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Ixazomib, Pomalidomide, and Dexamethasone Triplet Therapy in Patients with Double/Triple Refractory Myeloma
Read More
Conference Correspondent, ASH 2016 - Multiple Myeloma
Evaluation of Minimal Residual Disease in Relapsed/Refractory Multiple Myeloma Patients Treated with a Daratumumab-Based Regimen
Read More
Page 1 of 2
Results 1 - 10 of 19